• 126
  • 26
  • 收藏

U.S. authorizes Pfizer oral COVID-19 treatment, first for at-home use

Reuters2021-12-23

Dec 22 (Reuters) - The United States on Wednesday authorized Pfizer Inc's antiviral COVID-19 pill for at-risk people aged 12 and above, making it the first oral treatment and which can be taken at home, providing a potentially important tool in the fight against the fast-spreading Omicron variant.

Pfizer's antiviral regimen, Paxlovid, was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness, according to data from the company's clinical trial. Recent lab data suggests the drug retains its effectiveness against Omicron, Pfizer said.

Pfizer raised its 2022 production projections to 120 million courses of treatment from 80 million and said it was ready to start immediate delivery in the United States. The treatment's two-drug regimen includes a new medicine and a second older antiviral called ritonavir.

"Paxlovid's approval is a major milestone that marks another step towards making COVID-19 a much more manageable infection," said Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security.

"There are two key issues, however, that remain: It will be scarce in the coming weeks and its optimal use requires prompt diagnosis, which can be difficult with the continual testing problems that plague us," Adalja added.

Pfizer has said it has 180,000 treatment courses ready to ship this year. The U.S. government's contract for 10 million courses of the drug is priced at $530 per course.

The Food and Drug Administration's decision to issue emergency authorization for the treatment comes as the U.S. combats a surge in COVID-19 cases driven by the Omicron variant, with President Joe Biden announcing plans for more federal vaccination and testing sites.

The pills can fill a treatment gap opened by the Omicron variant, said William Schaffner, a leading infectious disease expert from the Vanderbilt University School of Medicine. The most widely used monoclonal antibody treatments for COVID-19 have proven to be less effective at fighting the variant and there is limited supply of the one remaining treatment that works, he said.

Monoclonal antibodies are typically given intravenously in hospitals, are not widely available and are more than twice the cost of the Pfizer pill.

The Omicron variant, first identified in southern Africa and Hong Kong in November, has spread across the world and now constitutes over 70% of new coronavirus cases in the United States, according to data from the U.S. Centers for Disease Control and Prevention. Prior infection and vaccines have been shown in studies to only partly prevent infection from the variant, though a booster shot does increase protection.

The FDA said it authorized Paxlovid for emergency use for the treatment of mild-to-moderate disease in adults and children 12 years and older, who are at high risk for progression to severe COVID-19.

The drug is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset, the FDA said. The pills are meant to be taken every 12 hours for five days beginning shortly after the onset of symptoms.

While the clinical trials did not include patients under the age of 18, Pfizer said, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of the drug in pediatric patients 12 and older weighing at least 40 kg (88.2 lbs).

The second drug, ritonavir, is known to have interactions with some other prescription medicines. Pfizer has said that should be manageable and suggested most patients would be able to lower the dose of their other medications while being treated for COVID-19.

Pfizer said it plans to file a new drug application with the FDA in 2022 for potential full regulatory approval. The European Union's drug regulator last week said that EU countries can use Paxlovid early after diagnosis of an infector, although the its full review of the drug has not been completed.

Pfizer has agreed to allow generic manufacturers to supply versions of the treatment to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). The generic versions are expected later next year.

A rival pill from Merck & Co is under review by the FDA. The drug, molnupiravir, developed with Ridgeback Biotherapeutics, cut hospitalization and death risk by 30% in a trial.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

举报

评论26

  • Eatmi
    ·2021-12-23
    Covid 19 makes stock market crazy... 
    回复
    举报
  • 214455ec
    ·2021-12-23
    This will help the economy to avoid lock downs 
    回复
    举报
  • RS142
    ·2021-12-23
    Good advancement
    回复
    举报
  • lizzy04
    ·2021-12-23
    Nice
    回复
    举报
  • PengsieX
    ·2021-12-23
    Convenience could be a dangerous thing 
    回复
    举报
    收起
    • PengsieX
      Given that there are errors even during vaccination, pills for home usage would be a huge problem as there will be individuals whom are unable to administered properly, as prescribed.
      2021-12-23
      回复
      举报
    • lizzy04
      why so?
      2021-12-23
      回复
      举报
  • PengsieX
    ·2021-12-23
    Hope no overdose incidents
    回复
    举报
  • 湖中有虎
    ·2021-12-23
    K
    回复
    举报
  • pekss
    ·2021-12-23
    MRK filed its pill for approval first but that isstill under review, while PFE’s pill filed later has been approved due to its higher effectiveness. Think MRK share price is going to be under pressure tonight.
    回复
    举报
    收起
    • maroketo
      It is time to give up the vaccine stocks and buy the stocks of tourism and airlines.
      2021-12-23
      回复
      举报
    • huuou
      The correct way is to buy the shares of two companies at the same time.
      2021-12-23
      回复
      举报
    • uuunited
      Vaccination benefits everyone in the world. The global economy needs recovery. MRK's stock price will rise.
      2021-12-23
      回复
      举报
    查看更多 1 条评论
  • JeffreyNeo
    ·2021-12-23
    1
    回复
    举报
    收起
  • Zlatan
    ·2021-12-23
    Oo
    回复
    举报
    收起
  • 394c833a
    ·2021-12-23
    😁
    回复
    举报
    收起
    • 394c833a
      😁
      2021-12-23
      回复
      举报
  • soosoo
    ·2021-12-23
    Good news
    回复
    举报
  • BlueDragon
    ·2021-12-23
    Glad to hear it
    回复
    举报
  • SillyOldBear
    ·2021-12-23
    Like pls
    回复
    举报
  • Henrywong
    ·2021-12-23
    👍
    回复
    举报
  • PatWong
    ·2021-12-23
    Sell
    回复
    举报
  • h20_mako
    ·2021-12-23
    🤔
    回复
    举报
    收起
    • Zlatan
      oo
      2021-12-23
      回复
      举报
    • Zlatan
      no
      2021-12-23
      回复
      举报
    • h20_mako
      👍
      2021-12-23
      回复
      举报
  • masran
    ·2021-12-23
    like pls
    回复
    举报
    收起
  • 天财寻者
    ·2021-12-23
    Nice
    回复
    举报
    收起
    • YWC
      J
      2021-12-23
      回复
      举报
  • Angela26
    ·2021-12-23
    like please 
    回复
    举报
    收起
    • Mimi2021
      Ok
      2021-12-23
      回复
      举报
 
 
 
 

热议股票

 
 
 
 
 

7x24